SEC Comment Letter 0000000000-24-009978 to BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI)
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: Sept. 3, 2024 · CIK: 0001137883 · Accession: 0000000000-24-009978
AI Filing Summary & Sentiment
File numbers found in text: 333-281827
Letter
September 3, 2024 Chaim Lebovits Chief Executive Officer Brainstorm Cell Therapeutics Inc. 1325 Avenue of Americas, 28th Floor New York, NY 10019 Re:Brainstorm Cell Therapeutics Inc. Registration Statement on Form S-3 Filed August 28, 2024 File No. 333-281827 Dear Chaim Lebovits: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Mayan Katz, Esq.
Show Raw Text
September 3, 2024
Chaim Lebovits
Chief Executive Officer
Brainstorm Cell Therapeutics Inc.
1325 Avenue of Americas, 28th Floor
New York, NY 10019
Re:Brainstorm Cell Therapeutics Inc.
Registration Statement on Form S-3
Filed August 28, 2024
File No. 333-281827
Dear Chaim Lebovits:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Mayan Katz, Esq.